Summary
15.77 0.18(1.12%)09/27/2024
ZIMV (ZIMV)
ZIMV (ZIMV)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
1.12 | 2.75 | 30.56 | -20.10 | -9.08 | 1.50 | 0.00 | 0.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 15.77 | |
Open | 15.81 | |
High | 15.96 | |
Low | 15.63 | |
Volume | 91,012 | |
Change | 0.18 | |
Change % | 1.12 | |
Avg Volume (20 Days) | 155,030 | |
Volume/Avg Volume (20 Days) Ratio | 0.59 | |
52 Week Range | 5.42 - 15.50 | |
Price vs 52 Week High | 1.71% | |
Price vs 52 Week Low | 190.87% | |
Range | 0.00 | |
Gap Up/Down | -0.21 |
Fundamentals | ||
Market Capitalization (Mln) | 430 | |
EBIDTA | 0 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 0.00 | |
Book Value | 0.0000 | |
Earnings Per Share | 0.0000 | |
EPS Estimate Current Quarter | 0.0000 | |
EPS Estimate Next Quarter | 0.0000 | |
EPS Estimate Current Year | 0.0000 | |
EPS Estimate Next Year | 0.0000 | |
Diluted EPS (TTM) | 0.0000 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | 0.0000 | |
Return on equity (TTM) | 0.0000 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 0 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 0.0000 | |
Revenue Enterprise Value | 0.0000 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 0 | |
Shares Float | 0 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 0.00 | |
Institutions (%) | 0.00 |
08/04 10:53 EST - seekingalpha.com
ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants David Saxon - Needham & Company Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants David Saxon - Needham & Company Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
07/23 08:00 EST - globenewswire.com
ZimVie Announces FDA Clearance and U.S. Launch of GenTekĀ® Restorative Components
Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings
ZimVie Announces FDA Clearance and U.S. Launch of GenTekĀ® Restorative Components
Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings
07/18 16:05 EST - globenewswire.com
ZimVie to Report Second Quarter Financial Results on August 1, 2024
PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
ZimVie to Report Second Quarter Financial Results on August 1, 2024
PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
05/16 16:05 EST - globenewswire.com
ZimVie to Participate in Upcoming Investor Conferences
PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences.
ZimVie to Participate in Upcoming Investor Conferences
PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences.
05/11 06:07 EST - seekingalpha.com
ZimVie Inc. (ZIMV) Q1 2024 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants Matt Miksic - Barclays Operator Good afternoon and welcome to ZimVie's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
ZimVie Inc. (ZIMV) Q1 2024 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants Matt Miksic - Barclays Operator Good afternoon and welcome to ZimVie's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
04/24 16:05 EST - globenewswire.com
ZimVie to Report First Quarter Financial Results on May 8, 2024
PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
ZimVie to Report First Quarter Financial Results on May 8, 2024
PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
04/01 08:00 EST - globenewswire.com
ZimVie Announces Closing of Sale of Spine Business
Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business
ZimVie Announces Closing of Sale of Spine Business
Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business
03/27 08:00 EST - globenewswire.com
ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference
WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference
WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
02/28 21:52 EST - seekingalpha.com
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
02/21 17:00 EST - globenewswire.com
ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
WESTMINSTER, Colo., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full-year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
WESTMINSTER, Colo., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full-year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
02/07 16:05 EST - globenewswire.com
ZimVie Announces Launch of Next-Generation TSXĀ® Implant in Japan
Newest implant innovation is designed for immediacy and peri-implant health Newest implant innovation is designed for immediacy and peri-implant health
ZimVie Announces Launch of Next-Generation TSXĀ® Implant in Japan
Newest implant innovation is designed for immediacy and peri-implant health Newest implant innovation is designed for immediacy and peri-implant health
12/26 19:21 EST - seekingalpha.com
ZimVie: Focusing On Higher Growth Dental Business (Rating Upgrade)
ZimVie's stock has doubled since reporting Q3 earnings, causing investors to wonder about the company's future. The company's Q3 revenues declined less than expected and the company raised full-year guidance. More importantly, ZimVie's decision to sell its spine business for $375 million jettisons an underperforming segment while solving a debt overhang.
ZimVie: Focusing On Higher Growth Dental Business (Rating Upgrade)
ZimVie's stock has doubled since reporting Q3 earnings, causing investors to wonder about the company's future. The company's Q3 revenues declined less than expected and the company raised full-year guidance. More importantly, ZimVie's decision to sell its spine business for $375 million jettisons an underperforming segment while solving a debt overhang.
11/01 21:57 EST - seekingalpha.com
ZimVie Inc. (ZIMV) Q3 2023 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call.
ZimVie Inc. (ZIMV) Q3 2023 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call.
10/31 08:00 EST - globenewswire.com
ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-CĀ® Cervical Disc
WESTMINSTER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the first patient in the United States has received the newly approved 4.5mm Mobi-CĀ® Cervical Disc. Introduced in France in 2004, Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. The smaller 4.5mm height Mobi-C implants, available in seven footprints to match patient anatomy, were approved by the FDA in August of this year.
ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-CĀ® Cervical Disc
WESTMINSTER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the first patient in the United States has received the newly approved 4.5mm Mobi-CĀ® Cervical Disc. Introduced in France in 2004, Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. The smaller 4.5mm height Mobi-C implants, available in seven footprints to match patient anatomy, were approved by the FDA in August of this year.
10/18 19:32 EST - investorplace.com
Brace for Impact: 7 Stocks to Sell Amid Rising Troubles
While it's an uncomfortable topic, every investor must face the prospect of stocks to sell. Like it or not, market success doesn't just come down to picking winners.
Brace for Impact: 7 Stocks to Sell Amid Rising Troubles
While it's an uncomfortable topic, every investor must face the prospect of stocks to sell. Like it or not, market success doesn't just come down to picking winners.
10/17 08:30 EST - globenewswire.com
ZimVie Announces the Launch of Azureā¢Ā Multi-Platform Product Solutions
New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio
ZimVie Announces the Launch of Azureā¢Ā Multi-Platform Product Solutions
New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio
10/12 13:32 EST - zacks.com
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
10/11 16:05 EST - globenewswire.com
ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023
WESTMINSTER, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 1, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023
WESTMINSTER, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 1, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
10/10 08:30 EST - globenewswire.com
ZimVie Announces the Recent Launch of Biotivityā¢ A/C Plus Membrane
New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market
ZimVie Announces the Recent Launch of Biotivityā¢ A/C Plus Membrane
New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market
09/26 08:00 EST - globenewswire.com
ZimVie Announces FDA Approval to Launch Mobi-CĀ® Hybrid Study
Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion
ZimVie Announces FDA Approval to Launch Mobi-CĀ® Hybrid Study
Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion